Drugs / ODM-209
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03878823 | Apr 2019 → Jan 2024 | castration-resistant prostate carcinoma, female breast carcinoma, metastatic neoplasm, metastatic prostate carcinoma | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ODM-209 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03878823 ↗ |
| Route | Oral | “co-administered with glucocorticoid and mineralocorticoid, orally daily” NCT03878823 ↗ |